| 領域 | 項目 | 靶點 | 適應癥 | 先進性 | 當前進度 |
|---|---|---|---|---|---|
| 靶向治療 | SI-B001 | EGFRxHER3雙特四價抗體 | 上皮腫瘤 | First-in-class | IIa期臨床 |
| 免疫治療 | SI-B003 | CTLA-4xPD-1雙特四價抗體 | 實體瘤 | Best-in-class | 即將進入II期臨床 |
| 靶向&免疫 | GNC-038 | CD19xPD-L1x4-1BBxCD3四特八價抗體 | 血液腫瘤、淋巴瘤 | First-in-class | 即將進入II期臨床 |
| GNC-039 | EGFRvlllxPD-L1x4-1BBxCD3四特八價抗體 | 腦膠質瘤 | First-in-class | I期臨床 | |
| GNC-035 | ROR1xPD-L1x4-1BBxCD3四特八價抗體 | 肺癌、三陰乳腺癌、胃癌、卵巢癌 | First-in-class | I期臨床 | |
| ADC藥物 | BL-B01D1 | EGFRxHER3雙抗ADC | 肺癌、食管癌、頭頸鱗癌 | First-in-class | I期臨床 |
| BL-M02D1 | Trop2單抗ADC | 非小細胞肺癌、三陰乳腺癌 | First-in-class | 2021Q4申報IND | |
| BL-M07D1 | HER2單抗ADC | 乳腺癌、胃癌 | First-in-class | 2022Q4申報IND | |
| COVID-19 | SI-F019 | 雙價人ACE2-Fc融合蛋白 | COVID-19、急性呼吸窘迫綜合征(ARDS)、肺動脈高壓(PAH) | First-in-class | IIa期臨床 |
